The Developmental Funds are used to promote strategic cancer-research initiatives that the Cancer Center Director and other senior Cancer Center members have deemed important for the overall success of Cold Spring Harbor Laboratory's cancer research program. An important use of these funds has been to support new faculty recruited to the Cancer Center and to promote development of new technologies, either within the research programs or in the Cancer Center Shared Resources. CSHL has a dynamic research environment with a relatively high turnover of faculty, compared to the traditional university model. This provides an opportunity to recruit outstanding young scientists at the beginning of their careers. The Developmental Funds are a critical component for this recruitment and have provided support for investigators who have gone on to establish vibrant and productive cancer-research programs. These investigators have been successful in obtaining independent funding to continue their research. An extremely valuable source of funding, the Developmental funds give the Cancer Center Director the flexibility to support novel projects and incorporate new technologies and approaches. This also significantly enhances the opportunity for investigators to pioneer new and exciting research directions. The Developmental Funds strengthen the Cancer Center initiatives by allowing the recruitment of additional new faculty, whose inventive research approaches complement and expand upon current cancer-research programs.
Developmental funds at the Cold Spring Harbor Laboratory are used primarily for recruitment of new faculty whose research can expand existing cancer research programs and move into new directions to promote the Cancer Center's mission to understand the underlying mechanisms of cancer as a means to developing strategies for therapeutic intervention.
|Chang, An-Yun; Castel, Stephane E; Ernst, Evan et al. (2017) The Conserved RNA Binding Cyclophilin, Rct1, Regulates Small RNA Biogenesis and Splicing Independent of Heterochromatin Assembly. Cell Rep 19:2477-2489|
|Mills, Alea A (2017) The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer. Cold Spring Harb Perspect Med 7:|
|Sheltzer, Jason M; Ko, Julie H; Replogle, John M et al. (2017) Single-chromosome Gains Commonly Function as Tumor Suppressors. Cancer Cell 31:240-255|
|Lee, Je H (2017) Quantitative approaches for investigating the spatial context of gene expression. Wiley Interdiscip Rev Syst Biol Med 9:|
|Lin, Ann; Giuliano, Christopher J; Sayles, Nicole M et al. (2017) CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. Elife 6:|
|Elkayam, Elad; Parmar, Rubina; Brown, Christopher R et al. (2017) siRNA carrying an (E)-vinylphosphonate moiety at the 5? end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2. Nucleic Acids Res 45:3528-3536|
|Fang, Han; Wu, Yiyang; Yang, Hui et al. (2017) Whole genome sequencing of one complex pedigree illustrates challenges with genomic medicine. BMC Med Genomics 10:10|
|Yuan, Zuanning; Riera, Alberto; Bai, Lin et al. (2017) Structural basis of Mcm2-7 replicative helicase loading by ORC-Cdc6 and Cdt1. Nat Struct Mol Biol 24:316-324|
|Chio, Iok In Christine; Tuveson, David A (2017) ROS in Cancer: The Burning Question. Trends Mol Med 23:411-429|
|Perurena, Naiara; Zandueta, Carolina; Martínez-Canarias, Susana et al. (2017) EPCR promotes breast cancer progression by altering SPOCK1/testican 1-mediated 3D growth. J Hematol Oncol 10:23|
Showing the most recent 10 out of 317 publications